Pending final contract, healthcare and pharmaceutical companies GSK and Sanofi announced an agreement with the UK government to supply 60 million doses of the partnership's COVID-19 vaccine, currently under development.
We update our COVID-19 vaccine progress every day on our progress page. Here's our weekly report.
Today Pfizer and BioNTech have jointly announced they are prepared to begin their Phase II/III global trials for their COVID-19 vaccine partnership. Following on review of Phase I/II trial results, the partnership worked with the FDA to select BNT162b2 as the vaccine candidate in the next phases.
The agreement will expand funding by up to $472 million in part to support the Phase 3 study of mRNA-1273, the company's COVID-19 vaccine. This funding expands on Moderna's previous agreement with BARDA for $483 million.
Pfizer and BioNTech biopharmaceutics announced today a $1.95 billion dollar agreement with the U.S. government for 100 million doses of the partnership's BNT162 program vaccine.
In a news release today, the BNT162b1 COVID-19 vaccine under development by Pfizer and BioNTech displayed early positive results in producing neutralizing antibodies from the partnership's Phase I/II trial.
Similar to several kinds of modern vaccines, the protein subunit vaccine improves on simplicity of the classic vaccine by removing the need to include viral particles at all.
In a press release from Oracle today, the computing and networking giant announced a partnership with The National Institute of Allergy and Infectious Diseases (NIAID) on a newly established COVID-19 Prevention Network or CoVPN.